Single dose vaccine, Sputnik Light, authorized for use in Russia

[vostok]

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

The single dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program between 5 December 2020 and 15 April 2021.

An efficacy level of almost 80% is higher than that of many two-dose vaccines.

Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.

Phase I/II of the Safety and Immunogenicity Study of the Sputnik Light vaccine has demonstrated that:

• Sputnik Light can elicit the development of antigen specific IgG antibodies in 96.9% of individuals on the 28th day after vaccination;
• The Sputnik Light vaccine elicits the development of virus neutralizing antibodies in 91.67% of individuals on the 28th day post immunization;
• Cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day;
• The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of the level of antigen specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization;
• No serious adverse events were registered after vaccination with Sputnik Light.

As of May 5, 2021, more than 20 million people globally have received their first shot of Sputnik V.

Sputnik Light is compatible with standard vaccine storage and logistics requirements, while also being affordable with a price of less than $10. The single dose regiment allows for immunization of a larger number of people in a shorter time frame, furthering the fight against the pandemic during the acute phase.

The Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective, with no long-term side effects, as confirmed in over 250 clinical trials conducted globally over the past two decades (while the history of use of human adenoviruses in vaccine development started in 1953).

The two dose Sputnik V vaccine remains the main vaccination tool.

Single dose vaccine, Sputnik Light, authorized for use in Russia

Single dose Sputnik Light vaccine against COVID-19 is the first component Sputnik V vaccine. Sputnik Light vaccine coronavirus was announced in May 2021 by the Gamaleya Center and the Russian Direct Investment Fund (RDIF) in Russia. | Official website vaccine against coronavirus Sputnik V.

sputnikvaccine.com

 

[dbc]

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

The single dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program between 5 December 2020 and 15 April 2021.

An efficacy level of almost 80% is higher than that of many two-dose vaccines.

Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.

Phase I/II of the Safety and Immunogenicity Study of the Sputnik Light vaccine has demonstrated that:

• Sputnik Light can elicit the development of antigen specific IgG antibodies in 96.9% of individuals on the 28th day after vaccination;
• The Sputnik Light vaccine elicits the development of virus neutralizing antibodies in 91.67% of individuals on the 28th day post immunization;
• Cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day;
• The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of the level of antigen specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization;
• No serious adverse events were registered after vaccination with Sputnik Light.

As of May 5, 2021, more than 20 million people globally have received their first shot of Sputnik V.

Sputnik Light is compatible with standard vaccine storage and logistics requirements, while also being affordable with a price of less than $10. The single dose regiment allows for immunization of a larger number of people in a shorter time frame, furthering the fight against the pandemic during the acute phase.

The Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective, with no long-term side effects, as confirmed in over 250 clinical trials conducted globally over the past two decades (while the history of use of human adenoviruses in vaccine development started in 1953).

The two dose Sputnik V vaccine remains the main vaccination tool.

Single dose vaccine, Sputnik Light, authorized for use in Russia

Single dose Sputnik Light vaccine against COVID-19 is the first component Sputnik V vaccine. Sputnik Light vaccine coronavirus was announced in May 2021 by the Gamaleya Center and the Russian Direct Investment Fund (RDIF) in Russia. | Official website vaccine against coronavirus Sputnik V.

sputnikvaccine.com

The second dose of Sputnik V is different from the first, the second dose uses adenovirus rAd5 and the first rAd26. If Russia is now going with a single dose regimen then which one are they planning to use rAd5 or rAd26? or both?

DEFINE_ME

 

[UKBengali]

Looks promising and since the price is the same as each of the standard 2 dose regimen, then more affordable.

@vostok - Looks really good and 80% efficacy is similar to the two-dose AstraZeneca vaccine. Do you have any idea when Russia may start exporting this new vaccine?
This would really help poor countries as 10 US dollars to get vaccinated will be less of a burden on their financial resources than most other vaccines.

 

[vostok]

The second dose of Sputnik V is different from the first, the second dose uses adenovirus rAd5 and the first rAd26. If Russia is now going with a single dose regimen then which one are they planning to use rAd5 or rAd26? or both?

DEFINE_ME

"The two dose Sputnik V vaccine remains the main vaccination tool."
The single one is for emergency cases.

Looks promising and since the price is the same as each of the standard 2 dose regimen, then more affordable.

@vostok - Looks really good and 80% efficacy is similar to the two-dose AstraZeneca vaccine. Do you have any idea when Russia may start exporting this new vaccine?
This would really help poor countries as 10 US dollars to get vaccinated will be less of a burden on their financial resources than most other vaccines.

No idea about export, but I suppose it will start soon.

 

[dbc]

"The two dose Sputnik V vaccine remains the main vaccination tool."
The single one is for emergency cases.

No idea about export, but I suppose it will be soon.

So I guess rAd26 first and then if required a follow up of rAd5?

 

[PakSword]

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

The single dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program between 5 December 2020 and 15 April 2021.

An efficacy level of almost 80% is higher than that of many two-dose vaccines.

Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.

Phase I/II of the Safety and Immunogenicity Study of the Sputnik Light vaccine has demonstrated that:

• Sputnik Light can elicit the development of antigen specific IgG antibodies in 96.9% of individuals on the 28th day after vaccination;
• The Sputnik Light vaccine elicits the development of virus neutralizing antibodies in 91.67% of individuals on the 28th day post immunization;
• Cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day;
• The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of the level of antigen specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization;
• No serious adverse events were registered after vaccination with Sputnik Light.

As of May 5, 2021, more than 20 million people globally have received their first shot of Sputnik V.

Sputnik Light is compatible with standard vaccine storage and logistics requirements, while also being affordable with a price of less than $10. The single dose regiment allows for immunization of a larger number of people in a shorter time frame, furthering the fight against the pandemic during the acute phase.

The Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective, with no long-term side effects, as confirmed in over 250 clinical trials conducted globally over the past two decades (while the history of use of human adenoviruses in vaccine development started in 1953).

The two dose Sputnik V vaccine remains the main vaccination tool.

Single dose vaccine, Sputnik Light, authorized for use in Russia

Single dose Sputnik Light vaccine against COVID-19 is the first component Sputnik V vaccine. Sputnik Light vaccine coronavirus was announced in May 2021 by the Gamaleya Center and the Russian Direct Investment Fund (RDIF) in Russia. | Official website vaccine against coronavirus Sputnik V.

sputnikvaccine.com

Even the first vaccine was extremely effective and safe. If Russia had developed a one dose vaccine, that will greatly help the world in fight against covid.

Russia needs to increase the production of its vaccines though. I would prefer Sputnik V over many other vaccines currently being administered.

 

[Peace be there]

Russia needs to increase the production of its vaccines though. I would prefer Sputnik V over many other vaccines currently being administered.

It is going to take time mate. I believe 30-40 % of the population in the poor countries will be vaccinated by then.

 

[dbc]

The two dose Sputnik V vaccine remains the main vaccination tool.

Apparently Russia is having trouble mass producing the second dose.


Mexico’s assistant health secretary, Hugo López-Gatell, said the Russians have found that the first adenovirus grows much more quickly than the second.

López-Gatell said Russian scientists are now pushing the idea of abandoning the idea of giving the two separate compounds several weeks apart and instead giving a second booster shot of the first compound six months apart, an approach called “Sputnik Light.”

Mexico cites Russia's Sputnik vaccine production problems

MEXICO CITY (AP) — Russian authorities have been having so many problems producing second doses of their Sputnik V coronavirus vaccine that Russia probably will be unable to supply enough to people who already got the first dose, Mexican officials said Monday.

apnews.com